Issue link: https://uberflip.scri.com/i/1529641
1125/24SCR018-7/R3 Abstract & Presentation Calendar ASH® 2024 6 Saturday Sunday Monday SUNDAY, DECEMBER 8 TH 4:30pm - 8:00pm Pacific Time (continued) Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 3458 Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi- Center, Global, Single-Arm, Phase Ib/ II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence Park JH Shaughnessy P Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 2880 Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/ Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007 Fathi AT Rotta M Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 3179 Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor Rein LA Rotta M Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 3215 Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies Bewersdorf JP Patel M, Philipovskiy A, Keiffer G Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4653 Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies Cortes D Matous JV Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 3366 Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDACTM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Dhakal B Matous JV Multiple Myeloma: Pharmacologic Therapies: Poster II